CEFTOLOZANE PHARMACOKINETICS IN A SEPTIC CRITICALLY ILL PATIENT UNDER DIFFERENT EXTRACORPOREAL REPLACEMENT THERAPIES.
Ceftolozane-tazobactam (C/T), a novel fifth-generation cephalosporin/β-lactamase inhibitor combination active against multidrug-resistant (MDR) Pseudomonas aeruginosa, is currently FDA-approved to treat complicated intra-abdominal and urinary tract infections at label dosage (1g/0.5g/8h intravenously), and also nosocomial and ventilator-associated pneumonia at high dose (2 g/1g/8h).….